在中国人群中,CYP2C9多态性与对缺血性中风的易感性有关
Jinglu Zhang1, Haiyu Jia1, Yun Liu1
1Gerontological Center, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China.
Annals of medicine
|October 30, 2025
概括
该CYP2C9 rs10509679 G>A变体与中国汉族人群中缺血性中风 (IS) 的风险较高有关. 这一发现可能有助于理解与CYP2C9遗传变异相关的IS易感性.
科学领域:
- 遗传学 是一个遗传学.
- 脑血管疾病 脑血管疾病
- 药物基因组学 药物基因组学
背景情况:
- 缺血性中风 (IS) 是全球死亡和残疾的主要原因.
- CYP2C9遗传变异与各种疾病发展有关.
- 在IS风险中CYP2C9变异的特定作用需要进一步澄清.
研究的目的:
- 调查CYP2C9遗传变异与中国汉族人群中缺血性中风易感性之间的关联.
- 确定影响IS风险的特定CYP2C9单核酸多态 (SNP).
主要方法:
- 病例控制研究涉及643名IS患者和643名健康对照.
- 使用MassARRAY iPLEX进行CYP2C9SNP (rs10509679,rs1934967,rs1934968,rs9332220) 的基因型鉴定.
- 后勤回归分析和哈普洛型分析,以评估与IS风险的关联.
主要成果:
- CYP2C9 rs10509679 G>A多态性与IS风险增加显著相关 (OR=1.48,p=0.024).
- 分层分析表明rs10509679与60岁以上,BMI<24的个体,吸烟者,饮酒者和非糖尿病人的更高IS易感性有关.
- 一个特定的单元型 (Ars10509679Crs1934967Grs1934968Grs9332220) 与IS的风险增加有关.
结论:
- CYP2C9 rs10509679 G>A 变体可能会导致缺血性中风的风险.
- 这项研究强调了特定的CYP2C9遗传变异在IS病变发生中的潜在作用.
- 需要进一步的研究来阐明CYP2C9与IS联系的确切机制.
相关概念视频
Single Nucleotide Polymorphisms-SNPs
17.9K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
17.9K
Genome-wide Association Studies-GWAS
15.3K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
15.3K
Comparing Copy Number Variations and SNPs
18.6K
Sequencing of the human genome has opened up several best-kept secrets of the genome. Scientists have identified thousands of genome variations that exist within a population. These variations can be a single nucleotide or a larger chromosomal variation.
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
18.6K
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
379
Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
379
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
192
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
192
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
245
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
245


